The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Nonsurgical Repigmentation Therapies in Vitiligo: Meta-analysis of the Literature
Abstract
OBJECTIVE: To assess the effectiveness and safety of nonsurgical repigmentation therapies in localized and generalized vitiligo by means of a meta-analysis. DATA SOURCES: Computerized searches of bibliographic databases, a complementary manual literature search, and contacts with researchers and pharmaceutical firms. STUDY SELECTION: Predefined selection criteria were applied to both randomized and nonrandomized controlled trials. DATA EXTRACTION: Two investigators independently assessed the articles for inclusion. When there was a disagreement, a third investigator was consulted. DATA SYNTHESIS: Sixty-three studies were found on therapies for localized vitiligo. Of these, 10 of 11 randomized controlled trials and 29 of 110 patient series were included. One hundred seventeen studies on therapies for generalized vitiligo were found. Of these, 10 of 22 randomized controlled trials and 46 of 231 patient series were included. Among randomized controlled trials on localized vitiligo, the pooled odds ratio vs placebo was significant for topical class 3 corticosteroids (14.32; 95% confidence interval [CI], 2.45-83.72). In the patient series, topical class 3 and class 4 corticosteroids carried the highest mean success rates (56% [95% CI, 50%-62%] and 55% [95% CI, 49%-61%], respectively). Side effects were reported mostly with topical psoralen and intralesional and class 4 corticosteroids. In the randomized controlled trials on generalized vitiligo, the odds ratio vs placebo was significant for oral methoxsalen plus sunlight (23.37; 95% CI, 1.33-409.93), oral psoralen plus sunlight (19.87; 95% CI, 2.37-166.32), and oral trioxsalen plus sunlight (3.75; 95% CI, 1.24-11.29). In the series, the highest mean success rates were achieved with narrowband UV-B (63%; 95% CI, 50%-76%), broadband UV-B (57%; 95% CI, 29%-82%), and oral methoxsalen plus UV-A therapy (51%; 95% CI, 46%-56%). Oral methoxsalen plus UV-A was associated with the highest rates of side effects. No side effects were reported with UV-B therapy. CONCLUSIONS: Class 3 corticosteroids and UV-B therapy are the most effective and safest therapies for localized and for generalized vitiligo, respectively.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Evidence based medicine: what it is and what it isn't
Sackett, D. L., Rosenberg, W. M. C., Gray, J. A. M., Haynes, R. B., & Richardson, W. S. (1996) · BMJ · doi:10.1136/bmj.312.7023.71 · Cited by 15,769
Evidence-Based Medicine: A New Approach to Teaching the Practice of Medicine
Guyatt, G. (1992) · JAMA · doi:10.1001/jama.1992.03490170092032 · Cited by 4,202
Publication bias in clinical research
Easterbrook, P. J., Gopalan, R., Berlin, J. A., & Matthews, D. R. (1991) · The Lancet · doi:10.1016/0140-6736(91)90201-y · Cited by 3,109 · cited 1×
“of patients 176 33 40 81 64 235 277 77 Patients with local side effects† Atrophy 0 0 0 0 0 5 (2) [1-5] 39 (14) [10-18] 26 (33) [22-43] Telangiectasia 0 0 0 0 0 0 8 (3) [1-5] 2 (3) [0-9] Corticosteroid acne 0 0 0 0 0 16 (7) [4-10] 25 (9) [6-12] 0 Hypertrichosis 0 0 0 0 0 2 (1) [0-3] 1 (1) [0-2] 0 Phototoxic reactions (…”
Systematic Reviews: Identifying relevant studies for systematic reviews
Dickersin, K., Scherer, R., & Lefebvre, C. (1994) · BMJ · doi:10.1136/bmj.309.6964.1286 · Cited by 2,256
Systematic Reviews: Rationale for systematic reviews
Mulrow, C. D. (1994) · BMJ · doi:10.1136/bmj.309.6954.597 · Cited by 1,677
The Medical Review Article: State of the Science
MULROW, C. D. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-106-3-485 · Cited by 856 · cited 6×
“of patients 34 72 Patients with side effects* Moon face 7 (21) [7-34] 1 (1) [0-8] Weight gain 5 (15) [5-31] 5 (7) [2-16] Acne 1 (3) [0-15] 2 (3) [0-10] Miscellaneous (systemic) 3 (9) [2-24] 11 (15) [7-24]”
BackgroundInfluentialThe Science of Reviewing Researcha
OXMAN, A. D., & GUYATT, G. H. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb26342.x · Cited by 472
The Relation between Systematic Reviews and Practice Guidelines
Cook, D. J., Greengold, N. L., Ellrodt, A. G., & Weingarten, S. R. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-3-199708010-00006 · Cited by 413
Treatment of Vitiligo With UV-B Radiation vs Topical Psoralen Plus UV-A
Westerhof, W. (1997) · Archives of Dermatology · doi:10.1001/archderm.133.12.1525 · Cited by 370
Self-citationStern, R. S., & Lange, R. (1988) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12464137 · Cited by 334
PASRICHA, J. S., & KHAITAN, B. K. (1993) · International Journal of Dermatology · doi:10.1111/j.1365-4362.1993.tb02754.x · Cited by 164
Practice Policies—What Are They?
Eddy, D. M. (1990) · JAMA · doi:10.1001/jama.1990.03440060125045 · Cited by 139
Identifying relevant studies for systematic reviews
Counsell, C. E., & Fraser, H. (1995) · BMJ · doi:10.1136/bmj.310.6972.126 · Cited by 132
Response to cosmetic disfigurement: patients with vitiligo.
Porter, J. R., Ah, B., Lerner, A. B., & Nordlund, J. J. (1987) · PubMed · Cited by 122
Clinical decision making: from theory to practice. Practice policies --what are they?
Eddy, D. M. (1990) · JAMA · doi:10.1001/jama.263.6.877 · Cited by 117
British Photodermatology Group guidelines for PUVA
Abel, E. (1995) · Journal of the American Academy of Dermatology · doi:10.1016/0190-9622(95)90203-1 · Cited by 115
An Approach to the Treatment of Vitiligo by Khellin
Abdel-Fattah, A., Aboul-Enein, M. N., Wasset, G. M., & El-Menshawi, B. S. (2009) · Dermatologica · doi:10.1159/000249932 · Cited by 95
Guidelines of care for vitiligo
Task Force (1996) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(96)90691-x · Cited by 93
Guidelines of care for phototherapy and photochemotherapy
a, & b (1994) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(08)81729-x · Cited by 57
Guidelines for the Treatment of Vitiligo
Antoniou, C., & Katsambas, A. (1992) · Drugs · doi:10.2165/00003495-199243040-00005 · Cited by 54
Photocarcinogenicity of psoralens used in PUVA treatment: Present status in mouse and man
Young, A. R. (1990) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/1011-1344(90)85093-c · Cited by 47
Treatment of Vitiligo with Oral Corticosteroids
Imamura, S., & Tagami, H. (2009) · Dermatologica · doi:10.1159/000251114 · Cited by 43
Nordlund, J. J., Halder, R. M., & Grimes, P. E. (1993) · Dermatologic Clinics · doi:10.1016/s0733-8635(18)30279-1 · Cited by 39
Needed: Review Articles with More Scientific Rigor
Huth, E. J. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-106-3-470_2 · Cited by 28
The need for evidence‐based management of skin diseases
Ladhani, S. N. (1997) · International Journal of Dermatology · doi:10.1046/j.1365-4362.1997.00004.x · Cited by 18
Cited by
Vitiligo: Mechanisms of Pathogenesis and Treatment
Frisoli, M. L., Essien, K., & Harris, J. E. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-100919-023531 · Cited by 618
Hamzavi, I., Jain, H., McLean, D., Shapiro, J., Zeng, H., & Lui, H. (2004) · Archives of Dermatology · doi:10.1001/archderm.140.6.677 · Cited by 452
Taieb, A., Alomar, A., Böhm, M., Dell’Anna, M. L., De Pase, A., Eleftheriadou, V., Ezzedine, K., Gauthier, Y., Gawkrodger, D. J., Jouary, T., et al. (2013) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2012.11197.x · Cited by 450
Taïeb, A., & Picardo, M. (2009) · New England Journal of Medicine · doi:10.1056/nejmcp0804388 · Cited by 352
Whitton, M. E., Pinart, M., Batchelor, J., Leonardi-Bee, J., González, U., Jiyad, Z., Eleftheriadou, V., & Ezzedine, K. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003263.pub5 · Cited by 304
Metadata
- Authors
- Njoo, M. D., Spuls, P. I., Bos, J. D., Westerhof, W., & Bossuyt, P. M. M.
- Venue
- Archives of Dermatology
- Publisher
- American Medical Association (AMA)
- Published
- 1998-12-01
- Volume
- 134
- Issue
- 12
- Pages
- 1532-40
- ISSN
- 0003-987X
- OpenAlex
- W2056418327
- Cited by
- 258
- References
- 27
- FWCI
- 0.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.